Following news that the FDA urged the U.S. to put a quick COVID-19 test for Innova, which is widely used in the UK, into the bin, the UK government followed suit with an additional billions of pounds of deals with Innova. The inevitable speculation of avoiding it has begun.
Leading the indictment is the Guardian, who underscores many of the pitfalls of Innova’s rapid COVID-19 test and subtly speculates that the FDA’s stance will be protected by the MHRA and ultimately the British government. ..
“MHRA Special Approval for Innova Tests Repackaged and Deployed by NHS- Another review scheduled by June 22nd.. “
Guardian – Rapid Covid test used in a large UK program gets a bitter report from the US
As revealed yesterday, such news was music that was heard by shareholders of UK-based COVID-19 test stocks (Omega Diagnostics, Avacta, Abingdon Health, etc.).
In addition, speculation arose on social media, with unconfirmed reports claiming that MHRA was considering the situation.
… And MHRA is now in the case.
Innova over and out!
— Andrew (@AndyMLloyd) June 11, 2021
But, interestingly or not, the DHSC saved his face and tested the Innova in response to the controversial demands of MHRA’s long-documented concerns for special approval. I tried to defend it.
Media commentator John Dikes may not be the tea of all investors, but he justifies DHSC’s political reaction to this issue (once we tell him about this particular issue). I accept):
Innova withdraws from FDA in the U.S.
Click here for DHSC support. Rather, we could do more to convince us that they are taking the FDA’s investigation seriously. This requires proper risk assessment, not repeated rhetoric. pic.twitter.com/SaxvA8Bfis
— JonDeeksFMedSci 💙 (@deeksj) June 11, 2021
Our view: Science will beat political games, but it’s time for the UK to offer
When the FDA says something isn’t good, it tends to be bad.
The DHSC and the UK Government may appear to distract in the short term in the error catalog, but relying on their respective tests from Innova, re-badged by the NHS, is unpopular and unpopular. There is little doubt that it is logical. We hope to see this in the MHRA review.
For investors in Omega Diagnostics, Avacta and Abingdon Health, they have clearly been given a big boost and it’s time to do it.
Speculation begins that Britain will bottle Innova ahead of upcoming reviews
Source link Speculation begins that Britain will bottle Innova ahead of upcoming reviews